{"id":340045,"date":"2026-11-05T11:41:20","date_gmt":"2026-11-05T06:11:20","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=340045"},"modified":"2026-11-05T11:41:20","modified_gmt":"2026-11-05T06:11:20","slug":"over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/","title":{"rendered":"3 Over the Counter and Prescription Drug Maker, Plastic Piping Systems Maker and Passenger Car Leader Stocks With a Strong Future Roadmap: Marksans Pharma, Astral and Maruti Suzuki"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Marksans Pharma, Astral and Maruti Suzuki: ROE of 13.2% to 13.8% and FY22 to FY26 revenue CAGR of 10.6% to 20.1%. Prices as of 4 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three OTC drug, plastic pipe and passenger car stocks to watch are Marksans Pharma, Astral and Maruti Suzuki. Their return on equity ranges from 13.2% to 13.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 20.1%. Marksans Pharma has the highest return on equity at 13.8%, while Maruti Suzuki has the fastest revenue growth at 20.1% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>OTC drug, plastic pipe and passenger car stocks give investors a way to track businesses that sit close to everyday demand in India. Marksans Pharma, Astral and Maruti Suzuki cover an over the counter and prescription drug maker, a plastic piping systems maker and a passenger car leader.<\/p>\n<p>This list covers three OTC drug, plastic pipe and passenger car stocks with complete current figures: Marksans Pharma, Astral and Maruti Suzuki. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#What_Are_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\" title=\"What Are OTC Drug, Plastic Pipe and Passenger Car Stocks?\">What Are OTC Drug, Plastic Pipe and Passenger Car Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks_at_a_Glance\" title=\"OTC Drug, Plastic Pipe and Passenger Car Stocks at a Glance\">OTC Drug, Plastic Pipe and Passenger Car Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Why_Do_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do OTC Drug, Plastic Pipe and Passenger Car Stocks Have a Strong Roadmap in India?\">Why Do OTC Drug, Plastic Pipe and Passenger Car Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Why_Marksans_Pharma_Features_Among_These_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\" title=\"Why Marksans Pharma Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks\">Why Marksans Pharma Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Why_Astral_Features_Among_These_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\" title=\"Why Astral Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks\">Why Astral Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Why_Maruti_Suzuki_Features_Among_These_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\" title=\"Why Maruti Suzuki Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks\">Why Maruti Suzuki Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Marksans_Pharma_vs_Astral_vs_Maruti_Suzuki_on_Key_Financials\" title=\"Marksans Pharma vs Astral vs Maruti Suzuki on Key Financials\">Marksans Pharma vs Astral vs Maruti Suzuki on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Key_Risks_to_Check_Before_Investing_in_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\" title=\"Key Risks to Check Before Investing in OTC Drug, Plastic Pipe and Passenger Car Stocks\">Key Risks to Check Before Investing in OTC Drug, Plastic Pipe and Passenger Car Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Final_Thoughts_on_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\" title=\"Final Thoughts on OTC Drug, Plastic Pipe and Passenger Car Stocks\">Final Thoughts on OTC Drug, Plastic Pipe and Passenger Car Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#What_are_OTC_drug_plastic_pipe_and_passenger_car_stocks\" title=\"What are OTC drug, plastic pipe and passenger car stocks?\">What are OTC drug, plastic pipe and passenger car stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Which_OTC_drug_plastic_pipe_and_passenger_car_stocks_are_covered_in_this_list\" title=\"Which OTC drug, plastic pipe and passenger car stocks are covered in this list?\">Which OTC drug, plastic pipe and passenger car stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Why_do_OTC_drug_plastic_pipe_and_passenger_car_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do OTC drug, plastic pipe and passenger car stocks have a strong future roadmap in India?\">Why do OTC drug, plastic pipe and passenger car stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#How_has_Marksans_Pharma_performed_financially\" title=\"How has Marksans Pharma performed financially?\">How has Marksans Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#How_has_Astral_performed_financially\" title=\"How has Astral performed financially?\">How has Astral performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#How_has_Maruti_Suzuki_performed_financially\" title=\"How has Maruti Suzuki performed financially?\">How has Maruti Suzuki performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#What_risks_should_investors_check_before_buying_OTC_drug_plastic_pipe_and_passenger_car_stocks\" title=\"What risks should investors check before buying OTC drug, plastic pipe and passenger car stocks?\">What risks should investors check before buying OTC drug, plastic pipe and passenger car stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and-passenger-car-leader-stocks-roadmap-overlook-list\/#Is_this_list_of_OTC_drug_plastic_pipe_and_passenger_car_stocks_investment_advice\" title=\"Is this list of OTC drug, plastic pipe and passenger car stocks investment advice?\">Is this list of OTC drug, plastic pipe and passenger car stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\"><\/span><strong>What Are OTC Drug, Plastic Pipe and Passenger Car Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>OTC drug, plastic pipe and passenger car stocks are listed companies that make over-the-counter and prescription formulations, produce CPVC and PVC pipes, adhesives and bathware, and sell hatchbacks, sedans and utility vehicles through a vast sales and service network. Their earnings depend on export approvals, building activity and car demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks_at_a_Glance\"><\/span><strong>OTC Drug, Plastic Pipe and Passenger Car Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/marksans\/marksans-pharma-ltd-share-price-today\">Marksans Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">301.65<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,994<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">35.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.11<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/astral\/astral-ltd-share-price-today\">Astral<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,423.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38,267<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">66.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/maruti\/maruti-suzuki-india-ltd-share-price-today\">Maruti Suzuki<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,995<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">353,984<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Marksans Pharma trades at a P\/E below the industry P\/E, while Astral and Maruti Suzuki trade above it, which reflects the growth the market already expects. Readers comparing OTC drug, plastic pipe and passenger car stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in OTC drug, plastic pipe and passenger car stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do OTC Drug, Plastic Pipe and Passenger Car Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>OTC drug, plastic pipe and passenger car stocks have a strong roadmap in India because steady demand for generics overseas, growing building activity and a healthy car market keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Generics.<\/strong> Regulated markets buy dependable supply.<\/li>\n<li><strong>Plastic pipes.<\/strong> Homes and cities need piping.<\/li>\n<li><strong>Cars.<\/strong> A wide network supports steady sales.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Marksans_Pharma_Features_Among_These_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\"><\/span><strong>Why Marksans Pharma Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the OTC drug, plastic pipe and passenger car stocks on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.<\/p>\n<p>In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.<\/p>\n<p>Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P\/E of 24.9, below the industry P\/E of 35.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.<\/p>\n<p><strong>What to watch:<\/strong> Track export growth, new product approvals and plant utilisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Astral_Features_Among_These_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\"><\/span><strong>Why Astral Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the pharma, building and auto shares on this list, Astral is a leading maker of plastic piping systems and building products, with CPVC and PVC pipes, adhesives, sealants and bathware sold through a wide distribution network.<\/p>\n<p>The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P\/E of 66.5, above the industry P\/E of 36.4.<\/p>\n<p>Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.<\/p>\n<p><strong>What to watch:<\/strong> Watch PVC resin price trends and growth in the adhesives and paints businesses.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Maruti_Suzuki_Features_Among_These_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\"><\/span><strong>Why Maruti Suzuki Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Maruti Suzuki is India&#8217;s largest passenger car maker, selling a wide range of hatchbacks, sedans and utility vehicles through a vast sales and service network, and it also exports cars to many countries.<\/p>\n<p>Revenue rose from Rs 90,074 crore in FY22 to Rs 187,673 crore in FY26, a compound annual growth rate of 20.1%. Net profit grew from Rs 3,880 crore in FY22 to Rs 14,680 crore in FY26, which works out to a compound annual growth rate of 39.5%.<\/p>\n<p>In the June 2026 quarter, revenue grew 34.2% year on year to Rs 54,344 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 353,984 crore. The stock trades at a P\/E of 24.7, above the industry P\/E of 23.4.<\/p>\n<p><strong>Roadmap:<\/strong> The company is widening its utility vehicle range, adding hybrid and electric models and growing its exports from new capacity. A trusted brand and wide service reach support demand among first-time and repeat buyers.<\/p>\n<p><strong>What to watch:<\/strong> Follow monthly sales, utility vehicle mix, export volumes and progress on electric models.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Marksans_Pharma_vs_Astral_vs_Maruti_Suzuki_on_Key_Financials\"><\/span><strong>Marksans Pharma vs Astral vs Maruti Suzuki on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three OTC drug, plastic pipe and passenger car stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Marksans Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,533<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,033<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">420<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Astral<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,429<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,616<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">535<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Maruti Suzuki<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">90,074<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">187,673<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14,680<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Marksans Pharma posts the highest return on equity in this group at 13.8%. Maruti Suzuki combines the largest FY26 revenue at Rs 187,673 crore with the fastest revenue growth, a 20.1% compound annual rate. A useful habit with OTC drug, plastic pipe and passenger car stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several generic medicine, CPVC pipe and hatchback stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Marksans Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">626<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">866<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Astral<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,370<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,591<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Maruti Suzuki<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">40,493<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">54,344<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">34.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\"><\/span><strong>Key Risks to Check Before Investing in OTC Drug, Plastic Pipe and Passenger Car Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these OTC drug, plastic pipe and passenger car stocks, the main points are: Long-term pharma, building and auto shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Input costs.<\/strong> Metal and material prices can move margins.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter OTC drug, plastic pipe and passenger car stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_OTC_Drug_Plastic_Pipe_and_Passenger_Car_Stocks\"><\/span><strong>Final Thoughts on OTC Drug, Plastic Pipe and Passenger Car Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>OTC drug, plastic pipe and passenger car stocks work best when investors track growth, valuation and return on equity side by side. Marksans Pharma, Astral and Maruti Suzuki each have a clear plan to grow. Based on the 4 November 2026 close, Marksans Pharma trades at Rs 301.65, Astral at Rs 1,423.7 and Maruti Suzuki at Rs 11,995. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these OTC drug, plastic pipe and passenger car stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track OTC drug, plastic pipe and passenger car stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_OTC_drug_plastic_pipe_and_passenger_car_stocks\"><\/span><strong>What are OTC drug, plastic pipe and passenger car stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> OTC drug, plastic pipe and passenger car stocks are listed companies that make over-the-counter and prescription formulations, produce CPVC and PVC pipes, adhesives and bathware, and sell hatchbacks, sedans and utility vehicles through a vast sales and service network. Their earnings depend on export approvals, building activity and car demand. This list looks at three of them, Marksans Pharma, Astral and Maruti Suzuki, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_OTC_drug_plastic_pipe_and_passenger_car_stocks_are_covered_in_this_list\"><\/span><strong>Which OTC drug, plastic pipe and passenger car stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Marksans Pharma, Astral and Maruti Suzuki. Based on the 4 November 2026 close, Marksans Pharma traded at Rs 301.65, Astral at Rs 1,423.7 and Maruti Suzuki at Rs 11,995. Their return on equity ranges from 13.2% to 13.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 20.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_OTC_drug_plastic_pipe_and_passenger_car_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do OTC drug, plastic pipe and passenger car stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> OTC drug, plastic pipe and passenger car stocks have a strong roadmap in India because steady demand for generics overseas, growing building activity and a healthy car market keep widening the market for these companies. The main drivers are as follows. Generics. Regulated markets buy dependable supply. Plastic pipes. Homes and cities need piping. Cars. A wide network supports steady sales. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Marksans_Pharma_performed_financially\"><\/span><strong>How has Marksans Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P\/E of 24.9, below the industry P\/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Astral_performed_financially\"><\/span><strong>How has Astral performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore. The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P\/E of 66.5, above the industry P\/E of 36.4. Looking ahead, the company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Maruti_Suzuki_performed_financially\"><\/span><strong>How has Maruti Suzuki performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 90,074 crore in FY22 to Rs 187,673 crore in FY26, a compound annual growth rate of 20.1%. Net profit grew from Rs 3,880 crore in FY22 to Rs 14,680 crore in FY26, which works out to a compound annual growth rate of 39.5%. In the June 2026 quarter, revenue grew 34.2% year on year to Rs 54,344 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 353,984 crore. The stock trades at a P\/E of 24.7, above the industry P\/E of 23.4. Looking ahead, the company is widening its utility vehicle range, adding hybrid and electric models and growing its exports from new capacity. A trusted brand and wide service reach support demand among first-time and repeat buyers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_OTC_drug_plastic_pipe_and_passenger_car_stocks\"><\/span><strong>What risks should investors check before buying OTC drug, plastic pipe and passenger car stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying OTC drug, plastic pipe and passenger car stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Input costs. Metal and material prices can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_OTC_drug_plastic_pipe_and_passenger_car_stocks_investment_advice\"><\/span><strong>Is this list of OTC drug, plastic pipe and passenger car stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are OTC drug, plastic pipe and passenger car stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"OTC drug, plastic pipe and passenger car stocks are listed companies that make over-the-counter and prescription formulations, produce CPVC and PVC pipes, adhesives and bathware, and sell hatchbacks, sedans and utility vehicles through a vast sales and service network. Their earnings depend on export approvals, building activity and car demand. This list looks at three of them, Marksans Pharma, Astral and Maruti Suzuki, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which OTC drug, plastic pipe and passenger car stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Marksans Pharma, Astral and Maruti Suzuki. Based on the 4 November 2026 close, Marksans Pharma traded at Rs 301.65, Astral at Rs 1,423.7 and Maruti Suzuki at Rs 11,995. Their return on equity ranges from 13.2% to 13.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 20.1%.\"}},{\"@type\":\"Question\",\"name\":\"Why do OTC drug, plastic pipe and passenger car stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"OTC drug, plastic pipe and passenger car stocks have a strong roadmap in India because steady demand for generics overseas, growing building activity and a healthy car market keep widening the market for these companies. The main drivers are as follows. Generics. Regulated markets buy dependable supply. Plastic pipes. Homes and cities need piping. Cars. A wide network supports steady sales. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Marksans Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P\/E of 24.9, below the industry P\/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.\"}},{\"@type\":\"Question\",\"name\":\"How has Astral performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore. The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P\/E of 66.5, above the industry P\/E of 36.4. Looking ahead, the company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.\"}},{\"@type\":\"Question\",\"name\":\"How has Maruti Suzuki performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 90,074 crore in FY22 to Rs 187,673 crore in FY26, a compound annual growth rate of 20.1%. Net profit grew from Rs 3,880 crore in FY22 to Rs 14,680 crore in FY26, which works out to a compound annual growth rate of 39.5%. In the June 2026 quarter, revenue grew 34.2% year on year to Rs 54,344 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 353,984 crore. The stock trades at a P\/E of 24.7, above the industry P\/E of 23.4. Looking ahead, the company is widening its utility vehicle range, adding hybrid and electric models and growing its exports from new capacity. A trusted brand and wide service reach support demand among first-time and repeat buyers.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying OTC drug, plastic pipe and passenger car stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying OTC drug, plastic pipe and passenger car stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Input costs. Metal and material prices can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of OTC drug, plastic pipe and passenger car stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>OTC Drug, Plastic Pipe and Passenger Car Stocks with a strong future roadmap: Marksans Pharma, Astral and Maruti Suzuki. Compare price, valuation, return on equity and revenue growth as of 4 November 2026.<\/p>\n","protected":false},"author":28,"featured_media":340042,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[8593,3803,20307,20309,20308,9051,624,20305,20306],"class_list":["post-340045","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-astral","tag-best-stocks","tag-building-and-auto-shares","tag-cpvc-pipe-and-hatchback-stocks","tag-generic-medicine","tag-marksans-pharma","tag-maruti-suzuki","tag-otc-drug","tag-plastic-pipe-and-passenger-car-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["340042"],"rank_math_title":["OTC Drug, Plastic Pipe and Car Stocks"],"rank_math_description":["Compare 3 OTC drug, plastic pipe and passenger car stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 4 Nov 2026."],"rank_math_focus_keyword":["OTC drug, plastic pipe and passenger car stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-over-the-counter-and-prescription-drug-maker-plastic-piping-systems-maker-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=340045"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340045\/revisions"}],"predecessor-version":[{"id":340046,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/340045\/revisions\/340046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/340042"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=340045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=340045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=340045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}